Clinical Trial

Various Procedural Treatment Options for Androgenetic Alopecia

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Androgenetic alopecia (AGA)is the most common form of alopecia. It predominantly affects males, but there has been a significant surge in female preponderance too, over the last decade Minoxidil belong to the anti-hypertensive class but it also affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may stimulate the microcirculation around the hair follicles and induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth Topical administration of finasteride offers the potential to reduce systemic effects related to its mechanism of action by preferentially inhibiting 5-a reductase in the scalp, as has been suggested in recent years so in this study we are going to compare efficacy of topical minoxidil versus topical finasteride in treatment of androgenetic alopecia
Trial Details
NCT Number NCT06826001
Lead Sponsor Sheikh Zayed Medical College
Conditions Androgenetic Alopecia
Enrollment 190 participants
Start Date 2025-02
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-02-13